Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Curr Opin Mol Ther[TA])
923 results
  • Gene therapy: Have the risks associated with viral vectors been solved? [Editorial]
    Curr Opin Mol Ther. 2010 Dec; 12(6):637-8.Auman JT
  • Gene therapy has the potential to cure monogenic diseases through the replacement of the deleterious gene with a functional copy. While the field of gene therapy has been plagued by serious adverse events associated with therapy, it is hoped that new, safer viral vectors have reduced these risks greatly. However, recently published reports indicate that these new viral vectors are a potential ris…
  • Inflammation, stem cells and atherosclerosis genetics. [Review]
    Curr Opin Mol Ther. 2010 Dec; 12(6):712-23.Goldschmidt-Clermont PJ, Seo DM, … Velazquez OC
  • Atherosclerosis and its associated complications remain the primary cause of death in humans. Aging is the main contributor to atherosclerosis, compared with any other risk factor, yet the specific manner in which age increases risk (the 'aging-risk' mechanism) remains elusive. A novel concept for atherosclerosis risk implicates a lack of endothelial progenitor cell (EPC)-dependent arterial repai…
  • The emerging role of microRNAs in drug responses. [Review]
    Curr Opin Mol Ther. 2010 Dec; 12(6):695-702.Zhang W, Dolan ME
  • In recent years, pharmacogenomic research has begun to integrate genetics, gene expression and pharmacological phenotypes. MicroRNAs (miRNAs), 21- to 25-nucleotide, non-coding RNAs that are present in almost all metazoan genomes, are a class of gene regulators that downregulate gene expression at the post-transcriptional level. Experimental evidence for the role of miRNAs in regulating pharmacolo…
  • Small non-coding RNAs in disease development and host-pathogen interactions. [Review]
    Curr Opin Mol Ther. 2010 Dec; 12(6):684-94.Rederstorff M, Hüttenhofer A
  • Non-coding RNAs (ncRNAs) play critical roles in all physiological processes. Many ncRNAs have also been implicated in a variety of pathological disorders, including cancer. This review provides an overview of the roles of small ncRNAs in infectious diseases and genetic disorders, including diseases of the CNS and various cancers. There is a focus on the consequences of microRNA (miRNA) de-regulat…
  • New druggable targets in the Ras pathway? [Review]
    Curr Opin Mol Ther. 2010 Dec; 12(6):674-83.Matallanas D, Crespo P
  • Ras proteins are key elements in the regulation of cellular proliferation, differentiation and survival. Mutational activation of Ras or of components of its effector pathways are detected in one-third of human cancers and are essential for the genesis and maintenance of the tumoral phenotype. Research efforts have been dedicated to the development of therapeutic agents that inhibit aberrant Ras …
  • Cancer stem cells - A therapeutic target? [Review]
    Curr Opin Mol Ther. 2010 Dec; 12(6):662-73.Maitland NJ, Collins AT
  • Cancer stem cells (CSCs) form a highly tumorigenic core in most human tumors. Although there is no consensus regarding CSC phenotype from different tumor types, CSCs from different cancers share a primitive undifferentiated nature, including a capacity to expand and differentiate, albeit aberrantly, into the major cell types observed in the corresponding tumor. This review focuses on the developm…
  • Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet. [Review]
    Curr Opin Mol Ther. 2010 Dec; 12(6):654-61.Pander J, Guchelaar HJ, Gelderblom H
  • Cancer treatment has undergone revolutionary changes during the past decade, as a result of the introduction of tyrosine kinase inhibitors (TKIs) that selectively inhibit growth factor pathways critical for tumor growth. Unexpected toxicity profiles and disappointing response rates to these 'magic bullets' have prompted research to identify markers that can predict toxicity or response to such ag…
  • In vitro diagnostics in the development and use of cardiovascular medicines. [Review]
    Curr Opin Mol Ther. 2010 Dec; 12(6):639-46.Leadley RJ
  • The list of potential cardiovascular biomarkers has expanded dramatically in recent years; however, the number of regulatory agency-approved diagnostic tests that guide treatment has been relatively unchanged compared with this growth in the discovery of putative biomarkers. Surrogate biochemical endpoints such as LDL and HDL are included in the current guidelines of various regulatory agencies f…
  • The ethics of gene therapy: balancing the risks. [Review]
    Curr Opin Mol Ther. 2010 Oct; 12(5):578-85.Deakin CT, Alexander IE, Kerridge I
  • Gene therapy research is characterized by heightened uncertainty about the risks associated with the complex products involved, particularly the risk of genotoxicity. Recognizing that uncertainty concerning risks is inescapable in first-in-human clinical trials of gene therapy, decisions on how to balance the risks nevertheless must be made. Ethics can facilitate translational progress by, first,…
  • Gene therapy from the perspective of systems biology. [Review]
    Curr Opin Mol Ther. 2010 Oct; 12(5):570-7.Mac Gabhann F, Annex BH, Popel AS
  • Gene therapy research has expanded from its original concept of replacing absent or defective DNA with functional DNA to include the manipulation (increase or decrease) of gene expression by the delivery of modified genes, siRNA or other genetic material via multiple vectors, including naked plasmid DNA, viruses and even cells. Specific tissues or cell types are targeted in order to decrease the …
  • Gene therapy for liver cancer: clinical experience and future prospects. [Review]
    Curr Opin Mol Ther. 2010 Oct; 12(5):561-9.Sangro B, Prieto J
  • In contrast to the large quantity of preclinical evidence for efficacy, few gene therapy agents have reached clinical development for the treatment of primary and secondary liver cancer. This review discusses the published clinical trials that have explored the feasibility, safety and efficacy of gene therapy strategies for the treatment of liver cancer. Strategies include restoration of tumor su…
  • Adeno-associated virus for the treatment of muscle diseases: toward clinical trials. [Review]
    Curr Opin Mol Ther. 2010 Oct; 12(5):553-60.DiPrimio N, McPhee SW, Samulski RJ
  • Muscle diseases include muscular dystrophies, cardiomyopathies, neuromuscular and metabolic disorders. The loss of normal muscle structure and function is associated with significant morbidity and mortality. Patients with Duchenne muscular dystrophy usually lose ambulation in their teenage years, and frequently experience severe respiratory problems and heart failure in later stages of life. Thes…
  • The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. [Review]
    Curr Opin Mol Ther. 2010 Oct; 12(5):546-52.Ahmed AU, Alexiades NG, Lesniak MS
  • Gene therapy is a novel means of anticancer treatment that has led to preliminary positive results in the preclinical setting, as well as in clinical trials; however, successful clinical application of this approach has been hampered by the inability of gene delivery systems to target tumors and to deliver a therapeutic payload to disseminated tumor foci efficiently. Along with viral vector syste…
  • Cell therapy for peripheral arterial disease. [Review]
    Curr Opin Mol Ther. 2010 Oct; 12(5):538-45.Menasché P
  • Peripheral arterial disease remains an often devastating condition, particularly in patients with diabetes, because of the high rate of functional disability, amputation and death. For those patients for whom conventional endovascular or surgical revascularization procedures have been unsuccessful, new options are eagerly awaited, among which cell therapy has gained increasing interest. Most clin…
  • Oncolytic adenoviruses for the treatment of brain tumors. [Review]
    Curr Opin Mol Ther. 2010 Oct; 12(5):530-7.Gomez-Manzano C, Fueyo J
  • In recent years, oncolytic viruses have been genetically engineered to target cancer cells selectively. Adenovirus is one such oncolytic virus that is being tested in clinical trials for the treatment of cancer. The observation that cells infected with replication-competent adenoviruses undergo autophagy has provided new options for investigating the mechanism of adenovirus-induced cell death. It…
New Search Next